{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic7unbzlh7qseafggs5olvpcc4qfpgobowrprh3fnkytycq6uludm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmpw5vnu34e2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiewrhmyequpzgkbc2f3aaymubmzv5ryqvvvflqnlkqnervlayprjy"
    },
    "mimeType": "image/jpeg",
    "size": 158364
  },
  "path": "/news/2026-05-fda-enhertu-neoadjuvant-adjuvant-treatment.html",
  "publishedAt": "2026-05-25T20:20:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.",
  "title": "FDA approves Enhertu as neoadjuvant, adjuvant treatment for breast cancer"
}